Jaguar Animal Health Inc (JAGX : NASDAQ)
Common Stock
$8.91
USD
+6.24 (233.71%)
Last updated: 2026-09-23
Stock Reverse Split
7 days agoThis stock executed a 1-for-15 reverse split on September 17, 2026. Historical prices have been adjusted accordingly.
Follow JAGX
JAGX
Jaguar Animal Health Inc
WealthAwesomePerformance
1 Day
+233.71%
1 Week
+154.94%
1 Month
-34.87%
YTD
-75.04%
Key Statistics
Market Cap
$17.92M
52W High
$1281.00
52W Low
$2.35
P/E Ratio
0.00
50 Day MA
$13.22
200 Day MA
$202.37
Beta
-0.06
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/23/2026 | $15.43 | $19.46 | $8.50 | $8.91 | $8.91 | 11,569,900 |
| 9/21/2026 | $2.87 | $2.87 | $2.48 | $2.67 | $2.67 | 72,900 |
| 9/18/2026 | $2.76 | $3.16 | $2.65 | $2.71 | $2.71 | 232,300 |
| 9/17/2026 | $3.70 | $3.70 | $2.35 | $2.75 | $2.75 | 256,300 |
| 9/16/2026 | $3.52 | $4.67 | $3.13 | $3.50 | $3.50 | 295,300 |
| 9/15/2026 | $4.35 | $4.53 | $3.00 | $3.38 | $3.38 | 141,980 |
| 9/14/2026 | $4.65 | $5.04 | $4.47 | $4.79 | $4.79 | 30,087 |
| 9/11/2026 | $0.33 | $0.33 | $0.29 | $0.31 | $4.71 | 27,380 |
| 9/10/2026 | $0.37 | $0.37 | $0.31 | $0.32 | $4.79 | 50,020 |
| 9/9/2026 | $0.42 | $0.42 | $0.33 | $0.37 | $5.49 | 38,093 |
Analyst Price Targets
Based on 2 analysts covering JAGX · as of Sep 17, 2026
Wall Street analysts forecast JAGX stock price to rise 2846.1% over the next 12 months.
Consensus
Strong Buy4.50 / 5.00
Avg. Target
US$262.50
+2846.1% Upside
Current Price
US$8.91
Last close
Analyst Breakdown (2 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on JAGX's historical volatility
30-Day Vol
405.3%
Annualized
90-Day Vol
291.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$7.45
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$8.40 | US$2.07 – US$33.99 |
| 60 trading days | US$7.91 | US$1.09 – US$57.15 |
| 90 trading days | US$7.45 | US$0.66 – US$83.98 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Jaguar Animal Health Inc
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Financials
- Revenue (TTM)
- $27.82M
- EBITDA
- $-23.19M
- Profit Margin
- -130.85%
- ROE (TTM)
- -548.83%
- EPS (Diluted)
- 19011.08
- Book Value
- 1.36
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
🔄 Recent Splits
1-for-15
Sep 17, 2026
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About JAGX.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| BENF | Beneficient Class A Common Stock | $2.90 | +438.73% |
| WHLR | Wheeler Real Estate Investment Trust, Inc. | $5.44 | +190.91% |
| VSA | TCTM Kids IT Education Inc. | $3.64 | +83.84% |
| ARTL | Artelo Biosciences Inc | $7.31 | +76.14% |
| BFRG | Bullfrog AI Holdings, Inc. Common Stock | $0.95 | +58.33% |
| VTGN | VistaGen Therapeutics Inc | $0.37 | +46.54% |
| IPDN | Professional Diversity Network Inc | $5.42 | +38.97% |
| ONCO | Onconetix Inc | $0.91 | +38.93% |